Health Care & Life Sciences » Biotechnology | Sunesis Pharmaceuticals Inc.

Sunesis Pharmaceuticals Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
39,293.00
42,981.00
46,430.00
42,588.00
31,750.00
13,696
Other Current Assets
1,199.00
1,223.00
558.00
643.00
1,183.00
1,504
Total Current Assets
40,492.00
44,204.00
46,988.00
43,231.00
32,933.00
15,200
Net Property, Plant & Equipment
23.00
42.00
14.00
3.00
20.00
11
Other Assets
10.00
-
-
-
1,381.00
113
Total Assets
40,525.00
44,246.00
47,002.00
43,234.00
34,334.00
15,324
ST Debt & Current Portion LT Debt
9,018.00
9,257.00
7,834.00
3,333.00
7,204.00
Accounts Payable
953.00
-
2,453.00
1,871.00
1,697.00
Other Current Liabilities
24,001.00
18,624.00
8,712.00
5,735.00
3,777.00
Total Current Liabilities
33,972.00
27,881.00
18,999.00
10,939.00
12,678.00
Long-Term Debt
9,025.00
-
-
11,102.00
-
Other Liabilities
3,712.00
2,563.00
610.00
169.00
112.00
Total Liabilities
46,709.00
30,444.00
19,609.00
22,210.00
12,790.00
Common Equity (Total)
6,184.00
13,802.00
10,934.00
2,216.00
578.00
Total Shareholders' Equity
6,184.00
13,802.00
27,393.00
21,024.00
21,544.00
Total Equity
6,184.00
13,802.00
27,393.00
21,024.00
21,544.00
Liabilities & Shareholders' Equity
40,525.00
44,246.00
47,002.00
43,234.00
34,334.00
Preferred Stock (Carrying Value)
-
-
16,459.00
18,808.00
20,966.00

About Sunesis Pharmaceuticals

View Profile
Address
395 Oyster Point Boulevard
South San Francisco California 94080
United States
Employees -
Website http://www.sunesis.com
Updated 07/08/2019
Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Its efforts are currently focused primarily on the development of vosaroxin for the treatment of acute myeloid leukemia. The firms activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital.